Altimmune, Inc. (ALT)
NASDAQ · Healthcare
Altimmune, Inc. Operating Income 2010–2025
Altimmune, Inc. annual/quarterly operating income history and growth rate from 2010 to 2025. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Altimmune, Inc. operating income for the quarter ending September 30, 2025 was -20.9 M, a 15.78% decrease year-over-year.
- Altimmune, Inc. operating income for the twelve months ending September 30, 2025 was -90.4 M, a 3.96% decrease year-over-year.
- Altimmune, Inc. annual operating income for 2025 was -94.5 M, a 8.42% decrease from 2024.
- Altimmune, Inc. annual operating income for 2024 was -103.2 M, a 7.55% increase from 2023.
- Altimmune, Inc. annual operating income for 2023 was -95.9 M, a 9.33% increase from 2022.
- Altimmune, Inc. annual operating income for 2022 was -87.7 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Altimmune, Inc. Operating Income — FAQ
Altimmune, Inc. (ALT) operating income over the last 12 years — annual and quarterly figures with year-over-year growth and charts.
What is Altimmune, Inc.'s operating income?
Altimmune, Inc. (ALT) reported operating income of -$94M for fiscal 2025.
Where can I see ALT's operating income history?
The chart and table above show Altimmune, Inc.'s operating income by year and by quarter, including the growth rate.